Molina (MOH - Free Report) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $1.84 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +23.61%. A quarter ago, it was expected that this provider of Medicaid-related services would post earnings of $1.37 per share when it actually produced earnings of $1.51, delivering a surprise of +10.22%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Molina, which belongs to the Zacks Medical - HMOs industry, posted revenues of $11.08 billion for the quarter ended September 2026, surpassing the Zacks Consensus Estimate by 1.42%. This compares to year-ago revenues of $11.48 billion. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Molina shares have added about 26.6% since the beginning of the year versus the S&P 500's gain of 12.7%.
What's Next for Molina?While Molina has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Molina was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.69 on $12 billion in revenues for the coming quarter and $5.28 on $44.47 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - HMOs is currently in the top 19% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Cigna (CI - Free Report) , has yet to report results for the quarter ended September 2026. The results are expected to be released on November 5.
This health insurer is expected to post quarterly earnings of $7.46 per share in its upcoming report, which represents a year-over-year change of -4.7%. The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level.
Cigna's revenues are expected to be $73.53 billion, up 5.7% from the year-ago quarter.
In its upcoming report, Molina (MOH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.72 per share, reflecting a decline of 60.9% compared to the same period last year. Revenues are forecasted to be $10.93 billion, representing a year-over-year decrease of 4.8%.
The current level reflects a downward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Molina metrics that Wall Street analysts commonly model and monitor.
According to the collective judgment of analysts, 'Revenue- Premium revenue- Marketplace' should come in at $570.00 million. The estimate points to a change of -52.4% from the year-ago quarter.
The consensus among analysts is that 'Revenue- Premium tax revenue' will reach $509.00 million. The estimate indicates a year-over-year change of +0.6%.
Analysts forecast 'Revenue- Premium revenue- Medicaid' to reach $8.16 billion. The estimate indicates a change of +1.9% from the prior-year quarter.
Analysts predict that the 'Revenue- Premium revenue- Medicare' will reach $1.57 billion. The estimate points to a change of -2.6% from the year-ago quarter.
It is projected by analysts that the 'MCR - Medicaid' will reach 93.0%. The estimate compares to the year-ago value of 92.0%.
The consensus estimate for 'MCR - Medicare' stands at 92.8%. Compared to the present estimate, the company reported 93.6% in the same quarter last year.
Analysts expect 'MCR - Marketplace' to come in at 93.3%. The estimate is in contrast to the year-ago figure of 95.6%.
Analysts' assessment points toward 'Ending Membership by Program - Total' reaching 4.91 million. The estimate compares to the year-ago value of 5.63 million.
The average prediction of analysts places 'Ending Membership by Program - Medicaid' at 4.42 million. The estimate is in contrast to the year-ago figure of 4.64 million.
Based on the collective assessment of analysts, 'Ending Membership by Program - Medicare' should arrive at 227.20 thousand. Compared to the present estimate, the company reported 266.00 thousand in the same quarter last year.
The combined assessment of analysts suggests that 'Ending Membership by Program - Marketplaces' will likely reach 264.05 thousand. The estimate is in contrast to the year-ago figure of 713.00 thousand.
The collective assessment of analysts points to an estimated 'MCR - Total' of 93.0%. The estimate compares to the year-ago value of 92.6%.
View all Key Company Metrics for Molina here>>>
Over the past month, Molina shares have recorded returns of +6.3% versus the Zacks S&P 500 composite's +0.7% change. Based on its Zacks Rank #4 (Sell), MOH will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Molina Healthcare očekává ve 3. čtvrtletí meziroční pokles zisku na akcii o 60,9 % a tržeb o 4,8 %, zatímco poměr nákladů na zdravotní péči vzroste na 93 %.
Key Takeaways Molina Healthcare's Q3 earnings are projected to plunge 60.9%, with revenues expected to decline 4.8%.MOH's premium revenues are expected to fall 4.9%, while its medical care ratio is projected to rise to 93%.Molina Healthcare's membership is forecast to drop 12.7%, led by a 63% plunge in Marketplace enrollment. Molina Healthcare, Inc. (MOH - Free Report) is set to report its third-quarter 2026 results on Oct. 21, 2026, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at 72 cents per shareon revenues of $10.93 billion.
The third-quarter earnings estimate witnessed two downward revisions and no upward revisions over the past 60 days. The bottom-line projection indicates a year-over-year decline of 60.9%. Also, the Zacks Consensus Estimate for quarterly revenues implies a year-over-year decrease of 4.8%.
Image Source: Zacks Investment Research
For 2026, the Zacks Consensus Estimate for Molina Healthcare’s revenues is pegged at $44.47 billion, implying a decline of 2.1% year over year. The consensus mark for 2026 EPS is pegged at $5.28, indicating a 52.1% year-over-year decrease.
Molina Healthcare’searnings beat the consensus estimate in two of the trailing four quarters and missed twice, with the average surprise being negative 183.3%. This is depicted in the figure below.
Q3 Earnings Whispers for MOHOur proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here.
MOH currently has an Earnings ESP of -3.30% and a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
What’s Shaping MOH’s Q3 Results?The Zacks Consensus Estimate projects premium revenues to decline 4.9% year over year from $10.84 billion, as lower revenues from Medicare and Marketplace are expected to outweigh gains from Medicaid. Investment income is also expected to fall 7% to $100.4 million. In contrast, premium tax revenues are forecast to rise 0.6% to $509 million.
Profitability could face additional pressure, with the consensus estimate for the consolidated medical care ratio (MCR) at 93%, up from 92.6% in the year-ago quarter. A higher MCR means the company is expected to spend more on medical care relative to its premium revenue.
Membership trends also point to a weaker quarter. The Zacks Consensus Estimate calls for total membership to decline 12.7% year over year. Medicaid membership is expected to fall nearly 5%, while Medicare and Marketplace membership could drop 14.6% and 63%, respectively.
With premium revenues, investment income and membership all expected to decline, alongside a higher MCR, the company faces several headwinds heading into the third-quarter report. These pressures could weigh on earnings and make an earnings beat harder to achieve.
Stocks That Warrant a LookWhile an earnings beat looks uncertain for Molina Healthcare, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around:
Aveanna Healthcare Holdings Inc. (AVAH - Free Report) has an Earnings ESP of +3.28% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Aveanna Healthcare’s bottom line for the to-be-reported quarter of 20 cents indicates 33.3% year-over-year growth. It has witnessed one upward revision against no downward movement over the past 60 days. The consensus mark for revenues predicts a 9.9% increase from a year ago.
CVS Health Corporation (CVS - Free Report) has an Earnings ESP of +0.79% and a Zacks Rank of 3.
The Zacks Consensus Estimate for CVS Health’s bottom line for the to-be-reported quarter indicates a 1.3% increase from a year ago. The company’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 20.5%. The consensus estimate for CVS’ revenues is pegged at $105.04 billion, signaling a 2.1% increase.
Acadia Healthcare Company, Inc. (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank of 3.
The Zacks Consensus Estimate for Acadia Healthcare’s bottom line for the to-be-reported quarter is pegged at 46 cents per share, which remained stable over the past week. Its earnings beat estimates in each of the past four quarters, with an average surprise of 47%. ACHC’s revenues for the to-be-reported quarter are pegged at $869.26 million, a 2.1% increase from the year-ago period.
Společnost Molina má ve čtvrtletí končícím v září 2026 vykázat EPS ve výši 0,72 USD, což představuje meziroční pokles o 60,9 %, při tržbách 10,93 miliardy USD (-4,8 %).
The market expects Molina (MOH - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on October 21, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis provider of Medicaid-related services is expected to post quarterly earnings of $0.72 per share in its upcoming report, which represents a year-over-year change of -60.9%.
Revenues are expected to be $10.93 billion, down 4.8% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.36% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Molina?For Molina, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -3.30%.
On the other hand, the stock currently carries a Zacks Rank of #4.
So, this combination makes it difficult to conclusively predict that Molina will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Molina would post earnings of $1.37 per share when it actually produced earnings of $1.51, delivering a surprise of +10.22%.
Over the last four quarters, the company has beaten consensus EPS estimates two times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Molina doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Key Takeaways Molina Healthcare benefits from Medicaid contracts, Medicare Duals growth and recent contract wins.Molina Healthcare expects its G&A ratio to improve to 6.4% in 2026 from 6.6% in 2025.MOH faces elevated medical costs, while its forward P/E exceeds both industry and five-year median levels. Molina Healthcare, Inc. (MOH - Free Report) is well-positioned for growth, supported by contract wins, strategic acquisitions and solid cash generation capacity. The company operates in three segments: Medicaid, Medicare and Marketplace. Over the past six months, MOH stock has gained 32.9% compared with the industry’s 31.8% growth.
MOH – with a market cap of $10.6 billion — offers health insurance plans sponsored by the government for individuals and families. It focuses on delivering affordable and comprehensive coverage, especially for lower-income people.
Courtesy of solid prospects, MOH currently carries a Zacks Rank #3 (Hold) and a Value Score of B.
Where Do Estimates for MOH Stand?The Zacks Consensus Estimate for Molina Healthcare’s 2026 earnings is pegged at $5.29 per share. In the past 30 days, it has witnessed one upward estimate revision against none in the opposite direction. The consensus estimate for revenues is pegged at $44.5 billion for 2026. The 2027 revenue estimate is pegged at $48 billion, indicating a 7.9% year-over-year increase.
It beat earnings estimates in two of the past four quarters and missed twice.
MOH’s Growth DriversAn aging U.S. population is supporting long-term demand for government-sponsored healthcare coverage, particularly Medicare and dual-eligible plans. This creates a favorable backdrop for Molina Healthcare’s Medicare Duals business, which is becoming an increasingly important part of its portfolio. Medicare Duals delivered a second-quarter 2026 MCR of 90.7%, while the full-year MCR outlook was lowered to 92.2%. The business is also benefiting from $2 billion of MMP premium being converted into new products and incremental premium from recent contract wins.
Rising healthcare needs among low-income and dual-eligible populations are creating opportunities in Medicaid and integrated care. Molina Healthcare continues to expand through state Medicaid contracts and integrated duals offerings, with the renewal of its Wisconsin contract providing additional room to grow in the latter. The company also retained its $2 billion Illinois Managed Medicaid contract, reinforcing its presence in a major Medicaid market. Beyond organic growth, MOH has an active acquisition pipeline and plans to deploy capital toward accretive deals, supporting its longer-term goal.
Molina Healthcare continues to emphasize operating efficiency through its long-running restructuring and profitability initiatives. These efforts have steadily lowered its adjusted G&A ratio, which improved from 7.2% in 2023 to 6.7% in 2024 and further to 6.6% in 2025. Looking ahead, the company expects its full-year 2026 G&A ratio to improve to 6.4%.
MOH's balance sheet strength provides financial flexibility. Its cash and cash equivalents of $5 billion at the end of the second quarter of 2026 were much higher than the long-term debt of $3.8 billion. Operating cash inflow was $788 million in the first six months of 2026 against an outflow of $112 million in the prior-year period.
Risks for MOH StockThere are some factors, however, that investors should keep a careful eye on.
Molina Healthcare continues to face pressure from elevated medical costs, with its consolidated MCR rising to 91.6% in the first half of 2026 from 89.8% a year ago. Management also expects Medicaid MCR to remain elevated through 2026, which could weigh on margin recovery.
MOH trades at a premium valuation, with a forward P/E of 24.45X compared with the industry average of 16.13X and its five-year median of 14.69X. The stretched valuation may limit upside potential if earnings growth remains under pressure.
Stocks to ConsiderSome better-ranked stocks in the Medical space are BrightSpring Health Services, Inc. (BTSG - Free Report) , Globus Medical, Inc. (GMED - Free Report) and Centene Corporation (CNC - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.82 per share has witnessed six upward revisions in the past 30 days against no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for current-year revenues is pegged at $15.3 billion, suggesting 18.2% year-over-year growth.
The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.93 per share has witnessed three upward revisions in the past 30 days, against no movement in the opposite direction. GMED beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.9%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.8% year-over-year growth.
The Zacks Consensus Estimate for Centene’s current-year earnings of $4.89 per share has witnessed nine upward revisions in the past 30 days, against no movement in the opposite direction. CNC beat earnings estimates in each of the trailing four quarters, with an average surprise of 151.3%. The consensus estimate for current-year revenues is pegged at $196.3 billion, suggesting 0.8% year-over-year growth.
Molina ve 2. čtvrtletí překonala odhad zisku na akcii, ale tržby i počet členů klesly. Firma zároveň zvýšila celoroční výhled upraveného zisku na akcii na nejméně 5,25 USD.
A month has gone by since the last earnings report for Molina (MOH - Free Report) . Shares have lost about 1.7% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Molina due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Molina Healthcare reported second-quarter 2026 adjusted earnings per share (EPS) of $1.51, which beat the Zacks Consensus Estimate by 10.2%. The bottom line declined 72.4% from the year-ago period's level.
Revenues amounted to $10.9 billion, which decreased 4.8% year over year. The top line marginally missed the consensus mark by 0.08%.
Second-quarter earnings benefited from lower operating expenses. However, lower premium revenues, declining membership, and weaker investment income weighed on its performance.
MOH’s Q2 Operational UpdatePremium revenues of $10.2 billion decreased 5.7% year over year and missed the Zacks Consensus Estimate by 1.8%. The decline primarily reflected lower membership levels, partially offset by pricing actions.
As of June 30, 2026, total membership decreased 14.3% year over year to around 4.9 million and missed the Zacks Consensus Estimate by 1.6%. The health insurer witnessed a year-over-year decrease in customers across all segments, especially in Marketplace and Other.
Investment income declined 4.7% year over year to $101 million. The figure beat the Zacks Consensus Estimate by 1.8%.
Total operating expenses were $10.7 billion, down 2.9% year over year and slightly below our model estimate of $11 billion, driven by lower medical care costs. The adjusted general and administrative expense ratio increased to 6.5% from 6.1% a year ago. Interest expense increased 12.5% year over year to $54 million.
The consolidated MCR (medical costs as a percentage of premium revenues) was 92.2% in the reported quarter. It rose from 90.4% a year ago but was marginally below the Zacks Consensus Estimate of 92.5%.
Molina Healthcare’s adjusted net income decreased 73.8% year over year to $77 million.
MOH’s Q2 Financial UpdateMolina Healthcare exited the second quarter with cash and cash equivalents of $5 billion, which increased from the 2025-end level of $4.2 billion. Total assets of $16 billion rose from $15.6 billion as of 2025-end.
Long-term debt totaled $3.8 billion, which remained unchanged from the 2025-end level.
Total stockholders’ equity of $4.2 billion inched up from $4.1 billion at the end of 2025.
Net cash provided by operating activities was $788 million compared to net cash used in operating activities of $112 million in the prior-year period.
MOH’s 2026 GuidanceThe company's full-year 2026 premium revenue guidance has remained unchanged at about $42 billion, down roughly 2% from 2025.
Management expects 2026 GAAP earnings of at least $2.15 per diluted share, up from its previous guidance of at least $1.90. It also raised its full-year 2026 adjusted earnings guidance by $0.25 to at least $5.25 per diluted share.
MOH raised its 2026 adjusted net income guidance to $268 million from $256 million. It also increased its GAAP net income guidance to $110 million from the previous estimate of $97 million.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -27.16% due to these changes.
VGM ScoresAt this time, Molina has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. However, the stock has a score of B on the value side, putting it in the second quintile for value investors.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Molina has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Molina (MOH - Free Report) came out with quarterly earnings of $1.51 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $5.48 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +10.22%. A quarter ago, it was expected that this provider of Medicaid-related services would post earnings of $1.57 per share when it actually produced earnings of $2.35, delivering a surprise of +49.68%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Molina, which belongs to the Zacks Medical - HMOs industry, posted revenues of $10.87 billion for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.08%. This compares to year-ago revenues of $11.43 billion. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Molina shares have added about 30.5% since the beginning of the year versus the S&P 500's gain of 9.7%.
What's Next for Molina?While Molina has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Molina was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.01 on $11.06 billion in revenues for the coming quarter and $5.23 on $44.41 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - HMOs is currently in the top 10% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
The Joint Corp. (JYNT - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026.
This company is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents a year-over-year change of +283.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
The Joint Corp.'s revenues are expected to be $14.7 million, up 10.7% from the year-ago quarter.
Analysts on Wall Street project that Molina (MOH - Free Report) will announce quarterly earnings of $1.37 per share in its forthcoming report, representing a decline of 75% year over year. Revenues are projected to reach $10.88 billion, declining 4.8% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Molina metrics that are commonly tracked and forecasted by Wall Street analysts.
The consensus among analysts is that 'Revenue- Premium revenue- Marketplace' will reach $643.41 million. The estimate indicates a change of -46.4% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenue- Premium tax revenue' should arrive at $437.04 million. The estimate suggests a change of +1.4% year over year.
Analysts predict that the 'Revenue- Premium revenue- Medicaid' will reach $8.16 billion. The estimate indicates a year-over-year change of +1.6%.
According to the collective judgment of analysts, 'Revenue- Premium revenue- Medicare' should come in at $1.63 billion. The estimate indicates a change of +1.2% from the prior-year quarter.
The average prediction of analysts places 'MCR - Medicaid' at 92.9%. Compared to the present estimate, the company reported 91.3% in the same quarter last year.
The collective assessment of analysts points to an estimated 'MCR - Medicare' of 93.7%. Compared to the present estimate, the company reported 90.0% in the same quarter last year.
Analysts expect 'MCR - Marketplace' to come in at 84.9%. Compared to the current estimate, the company reported 85.4% in the same quarter of the previous year.
The consensus estimate for 'Ending Membership by Program - Total' stands at 5.00 million. The estimate is in contrast to the year-ago figure of 5.75 million.
It is projected by analysts that the 'Ending Membership by Program - Medicaid' will reach 4.48 million. Compared to the current estimate, the company reported 4.77 million in the same quarter of the previous year.
Analysts' assessment points toward 'Ending Membership by Program - Medicare' reaching 230.66 thousand. The estimate compares to the year-ago value of 267.00 thousand.
Analysts forecast 'Ending Membership by Program - Marketplaces' to reach 285.05 thousand. The estimate is in contrast to the year-ago figure of 690.00 thousand.
The combined assessment of analysts suggests that 'MCR - Total' will likely reach 92.5%. Compared to the present estimate, the company reported 90.4% in the same quarter last year.
View all Key Company Metrics for Molina here>>>
Molina shares have witnessed a change of +16.4% in the past month, in contrast to the Zacks S&P 500 composite's -0.6% move. With a Zacks Rank #3 (Hold), MOH is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
